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Abstract
Background: Cytomegalovirus retinitis is a common AIDS-associated illness, leading to blindness in up to 30% of
patients. This study was to investigate the prevalence and clinical management of the cytomegalovirus retinitis
associated with AIDS in a large municipality of China.
Methods: Clinical and laboratory data from 23 cytomegalovirus retinitis patients (35 eyes) out of 303 hospitalized
AIDS individuals in a single medical center were analyzed retrospectively. Two of 23 patients were diagnosed
cytomegalovirus retinitis just before hospitalization without anti-CMV therapy. Ganciclovir combined with the high
active anti-retroviral therapy was installed for treatment of cytomegalovirus retinitis after diagnosis was confirmed.
The data were analyzed by specialists and statistics was also applied.
Results: The prevalence of cytomegalovirus retinitis in hospitalized AIDS patients was 7.6% in this study. The level
of CD4
+ T lymphocytes was correlated well with the occurrence of cytomegalovirus retinitis, showing 16.8% (19/
113) (95% confidence interval: 10.4,25.0), 5.4% (3/56) (95% confidence interval: 1.1,14.9), and 1.4% (1/69) (95%
confidence interval: 0.0,7.8) occurrence in the patients with CD4
+ T lymphocyte counts < 50, 50~99, and 100~199
cells/μl, respectively. The mean CD4
+ T lymphocyte counts was 31.7 ± 38.6 cells/μl in 23 AIDS patients with
cytomegalovirus retinitis. Median CD4
+ T lymphocyte count is 20 cells/μl with inter-quartile range as (5, 36). Seven
patients died (11 eyes) and 16 patients (24 eyes) survived. The proportion of blindness and low vision in eyes
infected with cytomegalovirus retinitis respectively was 20.8% (5/24) and 29.2% (7/24) when they were diagnosed
in survivors. The ganciclovir therapy was effective in 16 patients (24 eyes). Clinical recovery of cytomegalovirus
retinitis was 41.7% (10/24) and clinical improvement 58.3% (14/24). After anti-CMV treatment, the proportion of
blindness or low vision was 16.7% (4/24).
Conclusions: The AIDS patients with CD4
+ T lymphocyte < 50 cells/μl had increased susceptibility to
cytomegalovirus associated retinitis. Cytomegalovirus retinitis is a serious disease causing blindness. The
cytomegalovirus retinitis in the AIDS patients was response well to ganciclovir therapy. We should check their eyes
routinely such as dilated fundus examination with an indirect ophthalmoscope in the AIDS patients with CD4
+
T lymphocyte counts < 50 cells/μl.
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Cytomegalovirus (CMV) is the largest genome of the
herpes viruses. In Shenzhen, China, CMV IgG positive
rate in volunteering blood donor is 98.5%[1]. People
with normal immune systems rarely develop clinical
symptoms or long-term sequelae after initial infection.
This latent status remains for their lifetime unless
individual suffers from a significant local or systemic
immunodeficiency, such as corticosteroid therapy, phar-
macologic immunosuppression, autoimmune disorders
and acquired immunodeficiency syndrome (AIDS). End-
organ disease caused by CMV occurs among persons
with advanced immunosuppression, typically those with
CD4
+ T lymphocyte counts <50 cells/μl who are either
not receiving or have failed to respond to active antire-
troviral therapy (ART). Other risk factors include pre-
vious opportunistic infections (OI) and high plasma
human immunodeficiency virus (HIV) RNA levels
(>100,000 copies/ml). In general, 25 to 42% of AIDS
patients in developed countries developed CMV retinitis
before introduce of ART and the incidence of CMV
retinitis has been decreased 55-95% in the ART era[2].
The incidence of CMV retinitis in India varied from 2
to 20% with the majority of patients receiving ART[3]
while the incidence of CMV retinitis in sub-Saharan
Africa varied from 0 to 19.6%[4,5]. It was also reported
that 19.8% of ART-treated patients developed CMV reti-
nitis in Thailand[6]. The variation of the incidence of
the CMV retinitis in developing countries could result
from access of diagnostics and health care funding, var-
ied ART regimes and standards in those countries,
immune status and genetic susceptibility of the AIDS
patients. Despite the ART has changed the incidence
and severity of CMV retinitis of AIDS patients, CMV
retinitis remains the most common cause for vision loss
in AIDS patients globally. Nowadays, 90% of HIV-
infected people live in the developing countries includ-
ing Southeast Asia. The prevalence of AIDS in China
has increased significantly for past decade. The case
numbers of HIV-infected patients increased 153.0% and
of diagnosed AIDS patients increased 209.9% from 2004
to 2007, reaching 38,201 and 9,781 cases, respectively[7].
However, there is the lack of epidemiological report on
the incidence of CMV retinitis in the AIDS patients in
China. In this retrospective study, CMV retinitis in 303
AIDS patients hospitalized in a single health center spe-
cialized for infectious diseases was analyzed, including
the prevalence, relationship between CMV retinitis and
CD4
+ T lymphocyte counts, CMV viral load in plasma,
clinical treatment regime and response to anti-CMV
therapy. This data reflects the incidence of CMV retini-
tis in AIDS patients and current status of clinical man-
agement on this opportunistic infection in China.
Methods
Study population
Total of 303 hospitalized AIDS patients (3 or 4 stage of
WHO classification, ART naive) were enrolled in this
study from October 2005 to December 2007 in Shanghai
Public Health Clinical Center. All the patients were
examined their eyes routinely and serum samples were
taken after they had been admitted to this hospital.
Their clinical information (age, mode of transmission,
CD4
+ T lymphocyte count, CMV viral load, CMV IgG,
CMV IgM, HIV viral load, examination of eyes) was col-
lected from medical record under their writing consent
(Table 1).
This study was a retrospective non-blind study con-
formed to the tenets of the Declaration of Helsinki. It
was approved by Institutional Ethics Review Board of
Shanghai Public Health Clinical Center (International
index IORG0006364).
Diagnosis of CMV retinitis
The CMV retinitis was diagnosed by experienced
ophthalmologists according to the medical history,
ophthalmoscopic appearance of typical retinopathy
(yellow-white retinal lesions with granular border or
arciform retinal lesion with or without hemorrhage
along with vessels[8]) and laboratory assessment of
immune status excluded HIV retinopathy, toxoplasmo-
sis retinitis, acute retinal necrosis, progressive outer
retinal necrosis, syphilitic retinochoroiditis. After
receiving ART, immunologic reconstitution uveitis
(IRU) may happen in some patients. IRU is defined as
the occurrence of a decrease in vision because of mod-
erate or severe vitritis, macular edema, epiretinal mem-
branes, keratic precipitate, neovascularization of the
optic disk or retina, posterior synechia and cataract in
patients whose CD4
+ T lymphocyte count has
increased after receiving ART[9]. The examinations
were performed including vision acuity examination
(The Snellen Eye Chart is read while standing 20 feet
from the chart.), the slit-lamp ophthalmoscope, indir-
ect ophthalmoscope (dilated fundus examination), fun-
dus photograph (taken to document progression or
regression). The level of CMV IgG and IgM and CMV
v i r a ll o a dw e r ea n a l y z e db yELISA and real-time quan-
titative PCR respectively. The CD4
+ T lymphocyte
count was done using the flowcytometry. HIV viral
load was also quantified using bDNA technology in all
patients. The diagnostic methods were compliant with
the standard of the AIDS Group of Society of Infec-
tious Diseases, Chinese Medical Association[10].
Twenty-three patients were confirmed CMV retinitis
(Table 1) and they were followed up once a week. Fol-
low-up continued for at least 6 months. If the AIDS
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Page 2 of 9Table 1 The clinical data of CMV retinitis patients with AIDS before ganciclovir therapy and after ganciclovir therapy
Patient Age Gender CD4
+ Mode Other HIV VL Log-HIV CMV- CMV- CMV VL Log-CMV Vision Acuity
ID (years) Count of OI (copies ml) IgM IgG (copies/ml)
(cells/μl) transmission
1 (bi) 55 M 157 S TB 1.78 × 10
3 7.48 Neg Pos 2.37 × 10
3 7.77 20/25(R), 20/32(L)
2 34 M 4 B PJP 3.60 × 10
5 12.79 Pos Pos Neg NA 20/32(L)
3 46 F 20 B TB 1.21 × 10
5 11.7 Neg Pos Neg NA 20/50(L)
4 37 M 6 S OFI,PFI 2.16 × 10
5 12.28 Neg Pos 6.24 × 10
3 8.74 20/63(L)
5 (bi) 33 M 53 B PFI 5.11 × 10
2 6.24 Neg Pos 3.65 × 10
3 8.20 20/63(R), 20/200(L)
6 34 M 99 B N 1.24 × 10
3 7.12 Neg Pos 5.75 × 10
3 8.66 20/250(R)
7 (bi) 42 M 7 S HZ,PJP, 1.71 × 10
4 9.75 Neg Pos 8.57 × 10
3 9.06 20/200(R), 20/100(L)
8 52 M 45 U TB 6.10 × 10
5 13.32 Neg Pos 2.51 × 10
3 7.83 20/25(R)
9 (bi) 26 M 28 S PC 7.74 × 10
4 11.26 Neg Pos 1.87 × 10
4 9.84 20/50(R), 20/50(L)
10 48 M 5 U PJP 1.67 × 10
4 9.72 Neg Pos 1.23 × 10
5 11.72 20/50(R)
11 (bi) 25 F 3 S N 1.80 × 10
5 12.1 Neg Pos Neg NA 20/200(R), 20/20(L)
12 35 M 28 S L,PI 3.87 × 10
4 10.56 Neg Pos 3.34 × 10
5 12.72 20/400(L)
13 (bi) 42 M 1 U FI 1.10 × 10
6 13.91 Neg Pos 1.08 × 10
5 11.59 20/50(R), HM/BE(L)
14 (bi) 34 M 97 S CM 3.81 × 10
4 10.55 Neg Pos 8.08 × 10
3 9.00 20/100(R), HM/BE(L)
15 26 M 36 S N 6.55 × 10
5 13.39 Neg Pos 2.04 × 10
3 7.62 HM/BE(L)
16 (bi) 25 M 5 S CMVM 2.56 × 10
4 10.15 Neg Pos 3.86 × 10
3 8.26 LP (bi)
17 (bi) 33 F 3 S CNSI 4.91 × 10
4 10.8 Neg Pos 3.37 × 10
4 10.43 20/63(R), 20/100(L)
18 73 F 17 S PJP 6.64 × 10
5 13.41 Neg Pos 1.31 × 10
3 7.18 20/200(L)
19 (bi) 59 M 16 S PJP 1.89 × 10
5 12.15 Neg Pos 6.50 × 10
6 15.69 20/200(R), 20/100(L)
20 (bi) 42 M 33 S FI 2.06 × 10
3 7.63 Neg Pos 1.69 × 10
6 14.34 20/200(R), HM/BE(L)
21 30 M 0 S PJP 2.73 × 10
5 12.52 Neg Pos 3.64 × 10
5 12.80 HM/BE(R)
22 (bi) 73 M 35 S PJP 6.64 × 10
5 13.41 Neg Pos 2.03 × 10
5 12.22 NA
23 59 M 30 S TB 2.50 × 10
4 10.13 Neg Pos 1.78 × 10
5 12.09 20/40(R)
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9Table 1 The clinical data of CMV retinitis patients with AIDS before ganciclovir therapy and after ganciclovir therapy (Continued)
Patient Time Time response to anti-CMV treatment/ CMV VL CD4
+ Counts* Vision Acuity*
ID HAART Received Anti-CMV Received treatment complications (copies/ml) (cells/μl)
(weeks) (weeks)
1 (bi) 72 4 Effective NO Neg 235 20/20(R), 20/20(L)
2 24 24 Effective NO Neg 58 20/20(L)
3 28 24 Effective NO Neg 248 20/20(L)
4 16 8 Effective IRU Neg 165 20/32(L)
5 (bi) 40 28 Effective NO Neg 227 20/20(R), 20/25(L)
6 24 24 Effective NO Neg 400 20/20(R)
7 (bi) 4 3 Effective IRU Neg 186 20/20(R), 20/20(L)
8 4 2 Effective NO Neg 460 20/20(R)
9 (bi) 12 6 Effective NO Neg 177 20/32(R), 20/32(L)
10 8 2 Effective NO Neg 166 20/32(R)
11 (bi) 8 8 Effective NO Neg 120 20/20(R), 20/20(L)
12 28 2 Effective NO Neg 121 20/32(L)
13 (bi) 20 2 Effective NO Neg 189 20/25(R), 20/400(L)
14 (bi) 12 12 Effective NO Neg Missing 20/32(R),CF/50 cm(L)
15 24 16 Effective Rel, RD Neg 182 20/50(L)
16 (bi) 20 8 Effective NO Neg 222 HM/BE(R),CF/BE(L)
17 (bi) 0* 0* NA NA NA NA NA
18 0* 0* NA NA NA NA NA
19 (bi) 2 1.3 NA NA NA NA NA
20 (bi) 6 0* NA NA NA NA NA
21 8 0* NA NA NA NA NA
22 (bi) 0* 0* NA NA NA NA NA
23 0* 0* NA NA NA NA NA
CD4
+ count: CD4
+ count when diagnosed CMV retinitis; CD4
+ count*: CD4
+ count when follow-up finished; Vision Acuity: vision acuity when diagnosed CMV retinitis; Vision Acuity*: vision acuity when follow-up
finished; HM/BE: hand movement/before eye; LP: light perception; NA: not available; bi: bilatéral; HIV VL: HIV viral load; CMV VL: CMV viral load; F: female; M: male; S: sexually transmission; B: blood infusion; U:
unknown; Other OI: other opportunistic infection; TB: tuberculosis; PJP: pneumocystis jiroveci pneumonia; OFI: oral fungal infection; PFI: pulmonary fungal infection; N: no other opportunistic infection but CMV
retinitis; HZ: herpes zoster; PC: pancreatitis; L: lymphoma; PI: pulmonary infection; FI: fungal infection; CM: cryptococcal meningitis; CMVM: CMV myelitis; CNSI: central nervous system infection; Time ART received: the
time of ART from beginning ART to ending the follow-up; Time Anti-CMV received: the time during anti-CMV treatment with ganciclovir; bi: bilateral; HIV VL: HIV viral load; CMV VL: CMV viral load; Log-HIV: Log-
transform of HIV viral load; Log-CMV: Log-transform of CMV viral load; CF/50 cm: count finger/50 cm; HM/BE: hand movement/before eye; CF/BE: count finger/before eye; NA: not available; 0* indicated that the
therapeutic regime was not started or less than one week and the patients were died shortly after admitted to the hospital; Rel: relapse; RD: retinal detachment; NO: no ocular complications
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9patients were discharged from hospital, they were fol-
lowed up in out-patient department.
Treatment of the CMV retinitis patients with AIDS
The ganciclovir therapy was installed for the patients
with CMV retinitis in combination with ART. Twenty-
one patients with CMV retinitis had received the ART
treatment. The other 2 CMV retinitis patients with
AIDS died soon, so there was not enough time to treat
them with ART. Ganciclovir (5 mg/kg) was administered
twice a day by intravenous injection for two to three
weeks (according to the severity) during the inductive
phase. Then ganciclovir (5 mg/kg) was given once a day
intravenously or ganciclovir (1000 mg) three times a day
orally during the maintenance phase. The therapy of
ganciclovir should be continued until the CMV retinitis
is completely inactive, the CD4
+ T lymphocyte counts
above 75-150 cells/μl at least 3 months, and the patient
on ART for 18 months[11].
Statistical analysis
Statistical analyses were conducted using SAS statistical
Software. Different prevalences of CMV retinitis
between 4 groups of AIDS patients according to differ-
ent levels of CD4
+ T lymphocyte counts were analyzed
using the Cochran-Armitage trend test. P values < 0.05
is considered to be a significant level.
Result
Prevalence of the CMV retinitis
Three hundred and three patients were all in clinical
stage 3 or 4 according to WHO disease staging system
for HIV infection (Table 2). The average age of patients
was 41.9 ±14.3 years, ranging from 25 to 73 years.
Twenty-three patients with CMV retinitis were diag-
nosed among 303 AIDS patients, 19 males (29 eyes) and
4 females (6 eyes). Two of 23 patients were diagnosed
CMV retinitis just before hospitalization without anti-
C M Vt h e r a p y .I n2 3p a t i e n t sw i t hC M Vr e t i n i t i s ,1 6
patients acquired their AIDS v i as e x u a l l yt r a n s m i s s i o n
(16/23 = 69.6%), 4 via blood infusion (4/23 = 17.4%)
and 3 with unknown history (3/23 = 13.0%). Unilateral
CMV retinitis was seen in 11 patients and bilateral in 12
patients. Other opportunistic infections in the cohort of
23 AIDS patients were tuberculosis, pneumocystis jiro-
veci pneumonia, oral fungal infection, pulmonary fungal
infection, herpes zoster, lymphoma, cryptococcal menin-
gitis, CMV myelitis, central nervous system infection
(Table 1).
The prevalence of CMV retinitis was 7.6% (23/303) in
this cohort study with 303 AIDS patients. No CMV reti-
nitis was observed in 65 patients with CD4
+ Tl y m p h o -
cyte counts between 350 to 200 cells/μla n do n eC M V
retinitis out of 69 patients with CD4
+ Tl y m p h o c y t e
counts between 199 to 100 cells/μl (prevalence 1.4%,
95% confidence interval: 0.0,7.8). The CMV retinitis
occurred in 3 out of 56 patients with CD4
+ Tl y m p h o -
cyte counts at level of 99 to 50 cells/μl (prevalence 5.4%,
95% confidence interval: 1.1, 14.9). Moreover, the CMV
retinitis was diagnosed in 19 out of 113 patients with
CD4
+ T lymphocyte counts < 50 cells/μl (prevalence
16.8%, 95% confidence interval: 10.4, 25.0) (Table 2).
Statistical analysis showed a trend that the prevalence of
CMV retinitis was significantly difference in the AIDS
patients with different levels of the CD4
+ T lymphocyte
counts (p < 0.001, Cochran-Armitage trend test).
Clinical manifestations pre- and post- HAART and anti-
CMV treatment
Twenty-three patients (35 eyes) suffered from incom-
plete loss of vision acuity to blindness during enrollment
of the study. In 23 CMV retinitis patients (35 eyes), the
vision acuity less than 20/400 defined blindness in 7
eyes and between 20/400 and 20/63 defined low vision
in 15 eyes. Yellow-white retinal lesions with granular
border were observed. There were 4 eyes with optic
neuritis and disc edema and retinal frosted branch angii-
tis in 7 eyes (Figure 1). Sclerosis and occlusion of retinal
vessels occurred at the later stage of CMV retinitis.
Keratic precipitates existed in 2 of 35 eyes by slit-lamp
microscopic examination.
Eighteen patients with the CMV retinitis had received
the ART and ganciclovir, 3 patients the ART without
ganciclovir and 2 patients neither ART nor ganciclovir.
Seven AIDS patients with CMV retinitis in 11 eyes
(include 3 patients without ganciclovir therapy and 2
patients without ganciclovir therapy and ART) died
within 2 weeks of enrollment because of systemic com-
plications and infections. Sixteen patients (24 eyes) had
clinical follow-up data available after varied duration of
anti-CMV treatment. The proportion of blindness and
low vision in eyes infected with CMV retinitis respec-
tively was 20.8% (5/24) and 29.2% (7/24) when they
were diagnosed in survivors. Clinical manifestations of
CMV retinitis had altered after treatment comparing to
clinical signs pre-treatment. In recovered patients,
hemorrhage and exudation were disappeared completely
Table 2 The occurrence of CMV retinitis in 303 AIDS
patients grouped by their CD4
+ T lymphocyte counts
No. of CD4
+
T cells (cells/μl)
No. of
cases
No. of CMV
retinitis patients
CMV retinitis
prevalence (95% CI) (%)
<50 113 19 16.8 (10.4,25.0)
50~99 56 3 5.4 (1.1,14.9)
100~199 69 1 1.4 (0.0,7.8)
200~350 65 0 0 (0.0,5.5)
95% CI: 95% confidence interval
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Page 5 of 9Figure 1 Typical retinal appearance of the patients with CMV retinitis. A yellow-white retinal necrosis with granulo-margin. B retinal frosted
branch angiitis. C white cotton-wool patches. D optic disc edema. E sclerosis and occlusion of retinal vessels. F fluorescence leakage by
fluorescent fundus angiography.
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Page 6 of 9and yellow-white retinal scars were formed in 10 eyes.
The visions in 23 of 24 eyes improved (95.8%) but the
visual acuity in 3 eyes was still lower than 20/400 and in
1 eye was 20/400. The proportion of blindness or low
vision was 16.7% (4/24) after anti-CMV treatment. IRU
(keratic precipitate and vitritis) occurred in 3 eyes (2
patients) out of 24 eyes (12.5%) after 8 to 20 weeks of
combined ART with anti-CMV treatment, Detachment
of retina was also observed in 1 out of 24 eyes (4.2%)
after discontinuation of the therapy. The CMV retinitis
was relapsed in one patient. The patient continued ART
for 6 weeks when he relapsed, but he was still
immunosuppressed.
Laboratory Evaluation
The average of HIV viral DNA load was 2.3 ± 3.0 × 10
5
copies/ml (median of 7.7 × 10
4)i na l lA I D Sp a t i e n t s
with CMV retinitis enrolled into this study. Further ana-
lysis on the log-transformation of this characteristic
derives a mean of 11.0 ± 2.2 for these twenty-three
patient cohort.
The mean CD4
+ T lymphocyte count was 31.7 ± 38.6
cells/μl in the AIDS patients with CMV retinitis. Median
CD4
+ T lymphocyte count is 20 cells/μl with inter-quar-
tile range as (5, 36). Two IRU patients showed an aver-
age CD4
+ T lymphocyte counts of 112 cells/μlw h e nt h e
diagnosis was confirmed, indicating reconstitution of
immune capacity after a combined ART with anti-CMV
treatment.
The average of CMV viral load at the study enroll-
ment was 4.8 ± 14.7 ×10
5 copies/ml in the AIDS
patients with retinitis. Further analysis on the log-trans-
formation of this characteristic derives a mean of 10.3 ±
2.5 for these 23 patients cohort.
The CMV-IgM in serum was negative in all but one
patient and CMV-IgG was positive in all patients with
CMV retinitis.
Clinical and laboratory data from 23 patients with
CMV retinitis before and after treatment were summar-
ized in Table 1.
Discussion
The CMV retinitis becomes one of the most prevalent
opportunistic infection in AIDS patients causing blind-
ness. The prevalence of CMV retinitis in the cohort of
303 hospitalized AIDS patients was 7.6% in a single
health center in Shanghai, China. It seemed that the
occurrence of CMV retinitis in this retrospective study
was lower than the prevalence reported in literatures
[12]. This prevalence may be over-estimated because the
limitation of subjects in our study. But we could find
the trend of CMV retinitis of patients in late stage of
AIDS. In our understanding from a point of view of
Chinese culture on their health and cost concern about
doctor’s visits, minor vision problem was and will not
be the main reason for the AIDS patients to seek medi-
cal attention in comparison with other vital signs and
symptoms at the later stage of disease course. Some
patients only visited the doctor when their diseases were
very serious. So many of them died from other infec-
tions or complications before CMV retinitis had been
diagnosed. For example, seven advanced AIDS patients
entered into the study died within 2 weeks after their
primary admission to the hospital. Currently there is no
well-organized epidemiological survey or study on the
prevalence of CMV retinitis in the AIDS patients in
C h i n a .S ot h ep r e v a l e n c eo fC M Vr e t i n i t i si nw h o l e
population of AIDS patients with different stages of dis-
ease in China still need to be identified. The results
from the study indicated the prevalence of CMV retini-
tis of AIDS patients when they came to hospital for
medical treatment. This study raises our awareness of
special attention to full examination of the entire retina
through a full dilated pupil using an indirect ophthalmo-
scope of AIDS patients in their first clinical visit since a
majority of CMV retinitis could be asymptomatic and
diagnosed only through clinical screening and ophthal-
mologic examination[8]. The study also implies the
importance and urgency to have national-wide epide-
miology survey on the prevalence of CMV retinitis and
to launch educational programs for AIDS patients to
gain basic knowledge on retinitis and other potential
opportunistic infection in their lifetime.
Seven patients died (11 eyes) and 16 patients (24 eyes)
survived. The proportion of blindness and low vision in
eyes infected with CMV retinitis respectively was 20.8%
(5/24) and 29.2% (7/24) when they were diagnosed in
survivors. The ganciclovir therapy was effective in 16
patients (24 eyes). After anti-CMV treatment, the pro-
portion of blindness or low vision was 16.7% (4/24). The
rate of blindness and low vision was high. CMV retinitis
is a serious disease causing blindness, but the vision
acuity of many patients will improve if anti-CMV ther-
apy provided promptly. The vision acuity after anti-
CMV in our study is the vision acuity while ending fol-
low-up, so there was limitation. But these results of
vision acuity showed the anti-CMV was effective.
Cotton wool patches are often observed in the early
stage[13]. It is important to keep in mind that it was
often difficult to distinguish the cotton wool patches or
hemorrhage along with retinal vessels in the early stage
of CMV retinitis from the retinopathy induced by HIV
infection. The white cotton wool patches identified in 3
eyes during the initial diagnosis had evolved into large
area of yellow-white retinal lesions two months later
without treatment of anti-CMV therapy. It becomes
clear that early retinopathy can not be ignored and
should follow-up closely in the ADIS patients.
Shi et al. BMC Infectious Diseases 2011, 11:326
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Page 7 of 9According with previous studies[14-16], our result
showed that prevalence of CMV retinitis was closely
related to the levels of CD4
+ Tl y m p h o c y t ec o u n t si n
303 AIDS patients in this cohort study. A routine ocular
examination should be performed in the AIDS patients
with CD4
+ T lymphocyte counts less than 50 cells/μl.
Taken together, the number of CD4
+ T lymphocyte in
peripheral blood is an empirical indicator on occur-
rence, progress, alleviation and regression of CMV reti-
nitis in clinical diagnostic and management. In our
study, CMV retinitis in 4 patients with CD4
+ T lympho-
cyte counts > 50 cells/μl were diagnosed without ART.
We should observe more cases to study the reason
about CMV retinitis diagnosed in high CD4
+ T lympho-
cyte counts patients such as race of people, age, compli-
cating other disease et al.
CMV viral load was quantified with the real-time PCR
assay to explore whether the level of CMV viral load in
blood was correlated to the severity of CMV retinitis in
this study. There was limitation to detect the level of
CMV viral load in blood, sometimes CMV in the blood
does not rule out the possibility of a different infection
in the eye. It was reported that the CMV-PCR assay had
a high predicting value with estimated sensitivity of 95%
in detecting untreated CMV retinitis if vitreous samples
were used[17]. However, the vitreous sampling proce-
dure has a risk to cause hemorrhage, infection and
vision acuity loss, and was difficult to obtain patient’s
consent. So vitreous sampling is reserved for unusual
cases with atypical features, where clinical findings are
ambiguous and there needs to be clarification between
other retinitis.
The choice of available drugs includes ganciclovir, fos-
carnet, cidofovir and fomivirsen. Because of cost and
supply issues of anti-CMV drugs, ganciclovir is still the
first-line anti-CMV drug for clinical management of
CMV retinitis associated with AIDS in this study. In
combination with antiretroviral medication, suppression
of CMV disease for a short-term and maintenance of
vision for a relatively long-term were achieved from this
study. The CMV viral loads in patients after anti-CMV
therapy were decreased below detectable level. Although
it is reported that intravitreal injection of ganciclovir or
intraocular implant of sustain-release ganciclovir
improved treatment efficacy and reduce side-effect of
the drug, this therapeutic procedure has neither been
applied in the study nor reported in other central hospi-
tals in China for treatment of CMV retinitis.
IRU is recognized as one of important causes of
visions loss[18,19]. Two cases of IRU (3 eyes) were diag-
nosed in our study (2/23). Their visions were 20/32, 20/
40, 20/40, respectively, and average CD4
+ T lymphocyte
count was 112 cells/μl while vitritis and uveitis were
observed. Goldberg reported that use of cidofovir
increased the risk of IRU by a factor of 3.3[20].
Although immune reaction to low level of CMV antigen
in infected eye is essential to IRU pathogenesis, its
mechanism is still not fully understood[18].
Conclusion
Even though authors acknowledged that the case num-
bers were relatively small in this cohort, it did illustrate
occurrence of CMV retinitis in advanced AIDS patients
in China. The occurrence of CMV retinitis was reversely
correlated with the level of CD4
+ T lymphocytes. The
CMV retinitis in the AIDS patients was response well to
ganciclovir therapy. We should check their eyes routi-
nely such as dilated fundus examination with an indirect
ophthalmoscope in the AIDS patients with CD4
+ T lym-
phocyte counts< 50 cells/μl. In this study, CD4
+ Tl y m -
phocyte counts in 4 patients with CMV retinitis were >
50 cells/μl (157 cells/μl, 53 cells/μl, 99 cells/μl, 97 cells/
μl separately). It would be best to check AIDS patients
with CD4
+ T lymphocyte counts < 200 cells/μl. Several
important factors such as the result of CMV detection
and CD4
+ T lymphocyte counts have been identified for
early clinical diagnosis of CMV retinitis when CMV reti-
nitis is not typical and prophylactic treatment of anti-
CMV drug is recommended when the CD4
+ T lympho-
cyte count is less than 50 cells/μl in AIDS patients. This
study also addressed the necessity and urgency of a
national wide epidemiological investigation on CMV
retinitis in AIDS patients in China.
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